Orforglipron vs. Ozempic

IV NAD+ > NMN ≈ NR > Oral NAD+ (poor bioavailability)

Oral NAD+ supplementation is largely ineffective — NAD+ cannot efficiently cross cell membranes when taken by mouth and is broken down before reaching target tissues. IV NAD+ bypasses this entirely but requires clinical administration. NMN and NR are the practical oral choices.

Most NAD+ discussions focus on adding more precursor — but an equally important lever is reducing NAD+ waste. NNMT (nicotinamide N-methyltransferase) is an enzyme that degrades NAD+ by methylating nicotinamide into MeNAM. High NNMT activity is associated with adiposity, metabolic dysfunction, and accelerated aging.

5-Amino-1MQ is a selective NNMT inhibitor. By blocking this enzyme, it preserves NAD+ that would otherwise be wasted — complementing the supply side (NMN/NR) with a demand-side optimization. The combination of NMN + 5-Amino-1MQ is considered more synergistic than stacking NMN + NR, which share the same conversion bottleneck.

Stacking NMN + NR is not particularly synergistic because they converge on the same intermediate (NMN) before reaching NAD+. You are essentially doubling precursor volume through the same bottleneck. The more effective strategy is: one precursor (NMN or NR) + one waste-reduction agent (NNMT inhibitor).

Choosing between Nad and Nmn depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.

Head-to-head clinical trial data between Nad and Nmn is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.

Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.